Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene.

Ceccherini I, Hofstra RM, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, et al.

Oncogene. 1994 Oct;9(10):3025-9. Erratum in: Oncogene. 1995 Mar 16;10(6):1257.

PMID:
8084609
2.

Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

Baumgartner-Parzer SM, Lang R, Wagner L, Heinze G, Niederle B, Kaserer K, Waldhäusl W, Vierhapper H.

J Clin Endocrinol Metab. 2005 Nov;90(11):6232-6. Epub 2005 Aug 23.

PMID:
16118333
3.

Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.

Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A.

J Clin Endocrinol Metab. 2004 Nov;89(11):5823-7.

PMID:
15531548
4.

The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.

Weinhaeusel A, Scheuba C, Lauss M, Kriegner A, Kaserer K, Vierlinger K, Haas OA, Niederle B.

Thyroid. 2008 Dec;18(12):1269-76. doi: 10.1089/thy.2008.0139.

PMID:
18976163
5.

Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.

Cebrian A, Lesueur F, Martin S, Leyland J, Ahmed S, Luccarini C, Smith PL, Luben R, Whittaker J, Pharoah PD, Dunning AM, Ponder BA.

J Clin Endocrinol Metab. 2005 Nov;90(11):6268-74. Epub 2005 Aug 9.

PMID:
16091499

Supplemental Content

Support Center